Micropace Pty Ltd

Arrhythmias impair quality of life for over 5% of the world’s population. At Micropace we believe that everyone should have access to diagnosis and management to enjoy an arrhythmia-free life. Micropace is a medical device manufacturer specialising in the field of Cardiac Electrophysiology. Our flagship product family, EPS320 are the global standard for cardiac stimulation. Our story started more than two decades ago when our medical director Dr Michael Cejnar developed his first computerised EP stimulator, the EPS220 in 1995 as an alternative device to be easier and quicker to use. Establishing Micropace Pty Ltd, to manufacture and supply his colleague electrophysiologists around Australia with his stimulator via Bard Australia. Since then Micropace has started exporting its products to Europe and Asia in 1998 and entered the US Market in 2002 where its presence has grown in partnership with industry leaders such as Bard Electrophysiology, GE Healthcare, Boston Scientific and Atricure Inc. to become, 8 years later, the US market leader in EP stimulators. Today, Micropace is the global leader in EP stimulators and the family of stimulators exports into 50 countries, including USA, most European Union countries, Asia Pacific, India, Japan and China, with over 800 installations in the US and 1500 worldwide. Our company’s success stems from our intimate knowledge of clinical cardiac electrophysiology and its practitioner’s needs allowing us to deliver products which are very easy to use and reliable, yet feature packed. We focus on engaging in a collaborative partnership with clinicians by offering innovative technologies that enable faster, easier procedures. We have a cross-disciplinary approach and an agile development team that supports clinical research and responds to customer feedback. Micropace is a global company with worldwide distribution partners and offices in California, Sydney, Australia and the EU. Visit http://micropaceep.com for more information.